UnitedHealth Group (NYSE:UNH) had its price objective lowered by investment analysts at Raymond James from $310.00 to $265.00 in a note issued to investors on Wednesday, BenzingaRatingsTable reports. The brokerage currently has a “strong-buy” rating on the healthcare conglomerate’s stock. Raymond James’ target price would indicate a potential upside of 23.66% from the stock’s current price.
UNH has been the subject of a number of other research reports. Stephens assumed coverage on shares of UnitedHealth Group in a research report on Monday, January 14th. They issued an “overweight” rating and a $287.00 target price for the company. ValuEngine downgraded shares of UnitedHealth Group from a “buy” rating to a “hold” rating in a research report on Wednesday, February 27th. Zacks Investment Research raised shares of UnitedHealth Group from a “hold” rating to a “buy” rating and set a $279.00 target price for the company in a research report on Saturday, January 5th. SunTrust Banks decreased their target price on shares of UnitedHealth Group to $300.00 and set a “buy” rating for the company in a research report on Wednesday. They noted that the move was a valuation call. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $310.00 price objective on shares of UnitedHealth Group in a research report on Tuesday, January 15th. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $293.05.
UnitedHealth Group stock traded down $6.67 during mid-day trading on Wednesday, reaching $214.29. The company’s stock had a trading volume of 7,933,579 shares, compared to its average volume of 4,673,633. The company has a market cap of $220.89 billion, a P/E ratio of 16.64, a price-to-earnings-growth ratio of 1.18 and a beta of 0.79. UnitedHealth Group has a 12 month low of $215.82 and a 12 month high of $287.94. The company has a current ratio of 0.73, a quick ratio of 0.73 and a debt-to-equity ratio of 0.64.
In other news, Director Richard T. Burke sold 15,000 shares of the firm’s stock in a transaction dated Thursday, January 17th. The shares were sold at an average price of $260.55, for a total transaction of $3,908,250.00. Following the completion of the sale, the director now owns 193,872 shares in the company, valued at approximately $50,513,349.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Richard T. Burke sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $257.32, for a total transaction of $1,286,600.00. Following the sale, the director now owns 182,454 shares of the company’s stock, valued at approximately $46,949,063.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,930 shares of company stock valued at $8,495,383. 0.87% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Oregon Public Employees Retirement Fund raised its stake in UnitedHealth Group by 50,446.5% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 53,349,795 shares of the healthcare conglomerate’s stock worth $214,000 after purchasing an additional 53,244,249 shares in the last quarter. Capital International Investors raised its stake in UnitedHealth Group by 223.0% in the 3rd quarter. Capital International Investors now owns 16,319,843 shares of the healthcare conglomerate’s stock worth $4,341,731,000 after purchasing an additional 11,267,910 shares in the last quarter. Norges Bank acquired a new stake in UnitedHealth Group in the 4th quarter worth about $2,343,175,000. BlackRock Inc. raised its position in shares of UnitedHealth Group by 3.1% in the 4th quarter. BlackRock Inc. now owns 69,831,381 shares of the healthcare conglomerate’s stock valued at $17,396,391,000 after buying an additional 2,123,417 shares in the last quarter. Finally, Rehmann Capital Advisory Group raised its position in shares of UnitedHealth Group by 26,088.2% in the 3rd quarter. Rehmann Capital Advisory Group now owns 1,723,185 shares of the healthcare conglomerate’s stock valued at $6,477,000 after buying an additional 1,716,605 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.
UnitedHealth Group Company Profile
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.
Featured Article: Do closed-end mutual funds pay dividends?
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.